Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 9;8(8):746–757. doi: 10.1002/sctm.18-0183

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Synovial fluid changes 3 months after MSC treatment. (A): Only a few of the factors characterized in SF changed after MSC treatment. Fold change in SF soluble factors concentration after MSC treatment is displayed; dotted line indicates levels at baseline. Friedman test with Dunn's test as post hoc was used for identifying significant changes (n = 7). (B, C): Levels of adiponectin (B) and IL12p40 (C) in SF decrease after MSC treatment (n = 7). (D): Levels of VEGF increase after MSC treatment (n = 7). (E): Pro‐inflammatory CD14 + CD16+ monocyte/macrophages tend to decrease after MSC treatment (n = 5). (B–E): p values shown for Wilcoxon signed‐rank test. Abbreviations: CCL1, chemokine (C‐C motif) ligand 1; HGF, hepatocyte growth factor; IL, interleukins; MCP‐1, monocyte chemoattractant protein 1; MMP, matrix metalloproteinases; MSC, mesenchymal stromal cell; PGE2, prostaglandin; TIMP, tissue inhibitor of metalloproteinases; VEGF, vascular endothelial growth factor.